Ying Du Sells 5,808 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 5,808 shares of Zai Lab stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total value of $208,449.12. Following the sale, the chief executive officer now owns 476,046 shares of the company’s stock, valued at approximately $17,085,290.94. This represents a 1.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Ying Du also recently made the following trade(s):

• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total transaction of $1,622,000.00.
• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00.

Zai Lab Price Performance

Zai Lab stock opened at $31.77 on Friday. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -11.47 and a beta of 1.07. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $39.77. The stock’s 50-day moving average is $32.72 and its 200-day moving average is $28.77.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Research analysts anticipate that Zai Lab Limited will post -2.58 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ZLAB. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a report on Thursday, March 27th. Scotiabank initiated coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, March 13th. Finally, Bank of America reaffirmed a “neutral” rating and set a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Zai Lab in the fourth quarter worth about $29,000. Public Employees Retirement System of Ohio boosted its holdings in Zai Lab by 20.8% in the 4th quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock worth $484,000 after acquiring an additional 3,179 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Zai Lab by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock valued at $1,496,000 after acquiring an additional 1,200 shares in the last quarter. Woodline Partners LP lifted its position in shares of Zai Lab by 9.4% during the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock worth $46,089,000 after purchasing an additional 151,835 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in shares of Zai Lab in the fourth quarter valued at $7,857,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.